Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease

Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease

Item
http://www.wikidata.org/entity/Q34636851
Update and new approaches in the treatment of Castleman diseaseClinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.iNKT cell defects in HHV-8-associated MCD.CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.Clinical management of HIV-associated hematologic malignancies.Cancer clinical trials in persons with HIV infection.Kaposi sarcoma herpesvirus pathogenesis.Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition.Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient.Experience with Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome in a Large Urban HIV Clinic in the United States: Case Series and Literature Review.
P2860

Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease

Item
http://www.wikidata.org/entity/Q34636851
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rituximab plus liposomal doxor ...... multicentric Castleman disease
@ast
Rituximab plus liposomal doxor ...... multicentric Castleman disease
@en
Rituximab plus liposomal doxor ...... multicentric Castleman disease
@nl
type
label
Rituximab plus liposomal doxor ...... multicentric Castleman disease
@ast
Rituximab plus liposomal doxor ...... multicentric Castleman disease
@en
Rituximab plus liposomal doxor ...... multicentric Castleman disease
@nl
prefLabel
Rituximab plus liposomal doxor ...... multicentric Castleman disease
@ast
Rituximab plus liposomal doxor ...... multicentric Castleman disease
@en
Rituximab plus liposomal doxor ...... multicentric Castleman disease
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Rituximab plus liposomal doxor ...... multicentric Castleman disease
@en
P2093
P2860
P304
P31
P356
10.1182/BLOOD-2014-07-586800
P407
P433
P478
P50
P577
P698
P932